Department of Orthopaedic and Trauma Surgery, Campus Bio-Medico University, Via Alvaro del Portillo, 200, 00128 Trigoria, Rome, Italy.
Curr Stem Cell Res Ther. 2012 Jul;7(4):272-81. doi: 10.2174/157488812800793054.
Mesenchymal stem cells isolated from amnion/amniotic fluid, umbilical cord blood, placental tissue, umbilical cord vein and the Wharton's Jelly are promising candidates for musculoskeletal tissue engineering of bone and cartilage tissues. The extracorporeal nature of this source avoids the ethical concerns that plague the isolation of embryonic stem cells. Moreover, the harvesting does not require the invasive and discomfort extraction procedures as well as patient risks that attend adult stem cell isolation. Current preclinical studies support the application of these cell-based therapies for the regeneration of musculoskeletal tissues. We performed a review of the literature to focus on actual knowledge and the future perspectives of the stem cells deriving from umbilical cord and placenta for musculoskeletal tissue engineering.
从羊膜/羊水、脐带血、胎盘组织、脐带静脉和华通氏胶中分离出的间充质干细胞是骨和软骨组织肌肉骨骼组织工程的有前途的候选物。这种体外来源避免了困扰胚胎干细胞分离的伦理问题。此外，这种来源的采集不需要进行侵入性和不适的提取程序，也不会像成人干细胞分离那样存在患者风险。目前的临床前研究支持将这些基于细胞的疗法应用于肌肉骨骼组织的再生。我们对文献进行了综述，重点介绍了源自脐带和胎盘的干细胞在肌肉骨骼组织工程中的实际知识和未来前景。
